Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 368

1.

Therapy-related leukemia and myelodysplasia: susceptibility and incidence.

Leone G, Pagano L, Ben-Yehuda D, Voso MT.

Haematologica. 2007 Oct;92(10):1389-98.

2.

Incidence and susceptibility to therapy-related myeloid neoplasms.

Leone G, Fianchi L, Pagano L, Voso MT.

Chem Biol Interact. 2010 Mar 19;184(1-2):39-45. doi: 10.1016/j.cbi.2009.12.013. Epub 2009 Dec 21.

PMID:
20026017
3.
4.

Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.

Krishnan A, Bhatia S, Slovak ML, Arber DA, Niland JC, Nademanee A, Fung H, Bhatia R, Kashyap A, Molina A, O'Donnell MR, Parker PA, Sniecinski I, Snyder DS, Spielberger R, Stein A, Forman SJ.

Blood. 2000 Mar 1;95(5):1588-93.

5.
7.

The incidence of secondary leukemias.

Leone G, Mele L, Pulsoni A, Equitani F, Pagano L.

Haematologica. 1999 Oct;84(10):937-45. Review.

8.

Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.

Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E, Bolwell B.

J Clin Oncol. 2006 Aug 1;24(22):3604-10.

PMID:
16877727
9.

Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment.

van Leeuwen FE.

Baillieres Clin Haematol. 1996 Mar;9(1):57-85. Review.

PMID:
8730551
10.

Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II.

Super HJ, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Pedersen-Bjergaard J, Philip P, Diaz MO, Rowley JD.

Blood. 1993 Dec 15;82(12):3705-11.

11.

Influence of DNA damage and repair upon the risk of treatment related leukemia.

Guillem V, Tormo M.

Leuk Lymphoma. 2008 Feb;49(2):204-17. doi: 10.1080/10428190701769657. Review.

PMID:
18231906
12.

Stem cell transplantation for leukemias following myelodysplastic syndromes or secondary to cytotoxic therapy.

de Witte T, Oosterveld M, Span B, Muus P, Schattenberg A.

Rev Clin Exp Hematol. 2002 Mar;6(1):72-85; discussion 86-7. Review.

PMID:
12060485
13.

11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop.

Bloomfield CD, Archer KJ, Mrózek K, Lillington DM, Kaneko Y, Head DR, Dal Cin P, Raimondi SC.

Genes Chromosomes Cancer. 2002 Apr;33(4):362-78.

PMID:
11921271
14.

Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.

Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersbøll J, Hansen SW, Hou-Jensen K, Nielsen D, Sigsgaard TC, et al.

Leukemia. 1993 Dec;7(12):1975-86.

PMID:
8255096
15.

Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?

Hake CR, Graubert TA, Fenske TS.

Bone Marrow Transplant. 2007 Jan;39(2):59-70. Epub 2006 Dec 4. Review.

PMID:
17143301
16.

Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks.

Smith MA, Rubinstein L, Ungerleider RS.

Med Pediatr Oncol. 1994;23(2):86-98. Review.

PMID:
8202047
17.

Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.

Le Deley MC, Suzan F, Cutuli B, Delaloge S, Shamsaldin A, Linassier C, Clisant S, de Vathaire F, Fenaux P, Hill C.

J Clin Oncol. 2007 Jan 20;25(3):292-300. Epub 2006 Dec 11.

PMID:
17159192
18.

Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.

Nevill TJ, Hogge DE, Toze CL, Nantel SH, Power MM, Abou Mourad YR, Song KW, Lavoie JC, Forrest DL, Barnett MJ, Shepherd JD, Nitta JY, Wong S, Sutherland HJ, Smith CA.

Bone Marrow Transplant. 2008 Nov;42(10):659-66. doi: 10.1038/bmt.2008.226. Epub 2008 Aug 4.

PMID:
18679372
19.

Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.

Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL.

J Clin Oncol. 2007 Feb 10;25(5):493-500.

PMID:
17290056
20.

Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.

Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR.

J Natl Cancer Inst. 2007 Feb 7;99(3):196-205.

PMID:
17284714

Supplemental Content

Support Center